Real-Life Effectiveness and Tolerability of Vildagliptin and Other Oral Glucose-Lowering Therapies in Patients with Type 2 Diabetes in Germany

Diabetes Therapy

Volumn 5, Issue 1, 2014, Pages 183-191

  Göke, Rüdiger ^a   Bader, Giovanni ^b   Dworak, Markus ^c  

^a Diabetes Center Dietersdorfer Weg 2   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Diabetes; Dipeptidyl peptidase 4 inhibitors; Endocrinology; Glycosylated hemoglobin; Observational study; Oral antidiabetes agents; Real life; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GERMANY; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84924619415     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0060-4     Document Type: Article

References (16)

1. Brinks R, Tamayo T, Kowall B, Rathmann W. Prevalence of type 2 diabetes in Germany in 2040: estimates from an epidemiological model. Eur J Epidemiol. 2012;27:791–7.
2. Waldeyer R, Brinks R, Rathmann W, Giani G, Icks A. Projection of the burden of Type 2 diabetes mellitus in Germany: a demographic modelling approach to estimate the direct medical excess costs from 2010 to 2040. Diabet Med. 2013;30:999–1008.
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.
4. Matthaei S, Bierwirth R, Fritsche A, Gallwitz B, Haring HU, Joost HG, et al. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes. 2009;117:522–57.
5. Ahren B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin’s action when added to metformin. Diabetes Obes Metab. 2011;13:193–203.
6. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249–55.
7. Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag. 2010;6:541–8.
8. McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011;5:e35–48.
9. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol. 2009;62:499–505.
10. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2009;10:37.
11. Ware JH, Hamel MB. Pragmatic trials—guides to better patient care? N Engl J Med. 2011;364:1685–7.
12. Mathieu C, Barnett AH, Brath H, Conget I, de Castro JJ, Göke R, et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract. 2013;67:947–56.
13. Bader G, Geransar P, Schweizer A. Vildagliptin more effectively achieves a composite endpoint of HbA <7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Res Clin Pract. 2013;100:e78–81.
14. Blüher M, Kurz I, Dannenmaier S, Dworak M. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabet. 2012;3:161–9.
15. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26.
16. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.